Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Fineline Cube Aug 17, 2026
Company Deals

Xbiome Strikes NewCo‑Style Technology Collaboration with Biogent Therapeutics for AI‑Driven Bispecific Antibody Development

Fineline Cube Aug 14, 2026
Company Deals

ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions

Fineline Cube Aug 14, 2026
Company Deals

IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics – Adding PEBL‑Based CAR‑T Cell Therapy Platform for T‑Cell Malignancies

Fineline Cube Aug 14, 2026
Company Deals

Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide’s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal

Fineline Cube Aug 13, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Drug

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients

Fineline Cube Aug 17, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company

GenScript’s Legend Biotech Appoints Three New Directors to Board

Fineline Cube Aug 5, 2022

Hong Kong-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) announced that its subsidiary...

Company Drug Legal / IP

Boehringer Ingelheim Wins Patent Infringement Ruling Against HEC Over Trajenta

Fineline Cube Aug 4, 2022

The China National Intellectual Property Administration (CNIPA) has ruled in favor of German pharmaceutical giant...

Company Drug

Zelgen’s Jacktinib Hits Phase IIb Endpoint in Myelofibrosis Study

Fineline Cube Aug 4, 2022

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced the successful completion of a pivotal Phase...

Company Medical Device

Wision A.I.’s Polyp Detection Software Secures NMPA Approval for Colonoscopy Use

Fineline Cube Aug 4, 2022

The National Medical Products Administration (NMPA) has approved China-based Wision A.I.’s intestinal polyp electronic colonoscopy...

Company Medical Device

Ethicon’s Hemostatic Granules Win NMPA Approval for Endoscopic Surgery Use

Fineline Cube Aug 4, 2022

The National Medical Products Administration (NMPA) has granted marketing approval to U.S. medical device firm...

Company Deals

Bloomage Biotech Terminates Medytox Pact Over Botox Supply Issues

Fineline Cube Aug 4, 2022

China-based Bloomage Biotech (SHA: 688363) announced that its wholly owned subsidiary, Gentix Limited, has issued...

Company Deals

WuXi Biologics Partners with AstraZeneca for Local Production of Evusheld

Fineline Cube Aug 4, 2022

China-based WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO), announced...

Company Deals

Structure Therapeutics Oversubscribes USD33m on Top of USD100m Series B Round

Fineline Cube Aug 4, 2022

Structure Therapeutics, a Sino-US firm formerly known as ShouTi Inc., announced the oversubscription of USD33...

Company Drug

Ascletis Pharma’s ASC10 Receives IND Approval for COVID-19 Treatment in US and China

Fineline Cube Aug 4, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) has provided updates on the clinical progress of ASC10,...

Company Drug Legal / IP

ProfoundBio Receives FDA Approval for PRO1184, Appoints New CMO

Fineline Cube Aug 4, 2022

China-based macromolecular targeted therapy developer ProfoundBio (Suzhou) Co., Ltd announced that it has received clinical...

Company

AstraZeneca’s H1 2022 Revenues Surge 48%, Led by Oncology and Vaccines

Fineline Cube Aug 4, 2022

UK-based AstraZeneca (AZ, NASDAQ: AZN) released its financial report for H1 2022, showing a 48%...

Company Drug

Lee’s Pharma Completes Enrollment for NVK-002 Myopia Trials in China

Fineline Cube Aug 3, 2022

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) announced the completion...

Company Drug

Lynk Pharma Gets NMPA Green Light for LNK01004 Atopic Dermatitis Study

Fineline Cube Aug 3, 2022

Hangzhou-based Lynk Pharmaceuticals Co., Ltd announced it has received approval from the National Medical Products...

Company Drug

Sciwind Biosciences’ XW003 Hits Phase II Trial Goals in Type 2 Diabetes Treatment

Fineline Cube Aug 3, 2022

Hangzhou-based biopharma Sciwind Biosciences Co., Ltd announced positive results from a 20-week Phase II trial...

Company Deals

Fosun Pharma’s Proxima AI Raises Over RMB 100M in Strategic Financing

Fineline Cube Aug 3, 2022

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) subsidiary Shanghai Proxima AI Technology...

Company Deals

Taibang Biologic Raises $300M in Post-Privatization Financing Round

Fineline Cube Aug 3, 2022

Taibang Biologic Group (NASDAQ: CBPO), a plasma specialist privatized by Centurium Capital in April 2021,...

Company Deals

Sironax Completes $200 Million Series B Financing for Age-Related Disease Therapies

Fineline Cube Aug 3, 2022

Beijing-based clinical-stage biotechnology company Sironax announced the completion of a $200 million Series B financing...

Company Deals

ImmVira Partners with China Resources Biopharmaceutical on Oncolytic Virus MVR-C5252 for Gliomas

Fineline Cube Aug 3, 2022

China-based biotech company ImmVira has entered into an exclusive partnership with compatriot firm China Resources...

Company Deals

Tus-Pharma to Acquire Sinotau Pharma for RMB 220 Million

Fineline Cube Aug 3, 2022

China-based Tus-Pharmaceutical Group Co., Ltd (SHE: 000590) has announced plans to acquire 100% of Guangdong...

Company Drug

Eli Lilly Files for Baqsimi Approval in China to Treat Severe Hypoglycemia

Fineline Cube Aug 3, 2022

Eli Lilly & Co. (NYSE: LLY) has submitted a market approval application to China’s Center...

Posts pagination

1 … 684 685 686 … 709

Recent updates

  • AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients
  • Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA
  • Fosun Pharma Launches Phase 2 Trial of FXS7553 DPP‑1 Inhibitor for COPD in China
  • Asieris Pharmaceuticals Wins FDA Clearance for APL‑2501, an Anti‑CLDN6/9 ADC in Advanced Solid Tumors
  • Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS‑4729, a Triple‑Agonist Peptide Drug for Type 2 Diabetes
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients

Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Company Drug

Fosun Pharma Launches Phase 2 Trial of FXS7553 DPP‑1 Inhibitor for COPD in China

Company Drug

Asieris Pharmaceuticals Wins FDA Clearance for APL‑2501, an Anti‑CLDN6/9 ADC in Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.